Company
Servier
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
3
3 still marketed
Novel approvals
3
Approvals since 2021
4
Originals and new uses
Phase 3 trials
24
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Voranigo approved NovelBreakthrough therapyPriority reviewOrphanAug 6, 2024
- Tibsovo new use Breakthrough therapyPriority reviewOrphanOct 24, 2023
- Tibsovo new use Breakthrough therapyPriority reviewOrphanMay 25, 2022
- Tibsovo new use Priority reviewOrphanAug 25, 2021
- Tibsovo new use Priority reviewMay 2, 2019
- Asparlas approved NovelOrphanDec 20, 2018
- Tibsovo approved NovelPriority reviewOrphanJul 20, 2018
Drugs in development (2)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
Recruiting Phase 3 trials
Largest first.
- An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.Pivotal-lookingRecruiting
Servier Affaires MédicalesIndustry
NCT05907057 · 245 participants (planned) · Start Jun 14, 2023 · Primary completion Oct 15, 2027
Drug: Ivosidenib 500mg Oral Tablet; Azacitidine · For: Acute Myeloid Leukemia (AML)
Sites: Vienna, Austria; Wels, Austria; Marseille, France · 15 sites in all
- Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment RegimensPivotal-lookingRecruiting
Servier Bio-Innovation LLCIndustry
NCT06127407 · 156 participants (planned) · Start Jul 9, 2024 · Primary completion Feb 1, 2028
Drug: Ivosidenib 500mg; Placebo · For: Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 115 sites in all
- Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 MutationPivotal-lookingRecruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT06465953 · 48 participants (planned) · Start Dec 3, 2024 · Primary completion Nov 1, 2027
Drug: Ivosidenib; Azacitidine · For: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS); Myelodysplastic Syndromes (MDS)
Sites: Denver, Colorado; Chicago, Illinois; Boston, Massachusetts · 62 sites in all
Marketed drugs (3)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.